The Osteoporosis Treatment Market was valued at $15.73 billion in 2024, expected to reach $20.99 billion by 2032, with a CAGR of 4.83%. The U.S. market was valued at $4.80 billion in 2024, projected to reach $6.24 billion by 2032, growing at a CAGR of 4.49%.

Osteoporotic fractures are increasing globally, especially in the elderly and postmenopausal, leading to immobility and higher mortality rates. The market for osteoporosis treatments is growing due to the need for preventative care and bone-strengthening treatments to reduce the risk of fractures.

The U.S. holds a dominant position in the North American market for osteoporosis treatments due to the high incidence of osteoporosis, particularly in elderly and postmenopausal patients.

Key companies profiled in the report include Amgen Inc., Eli Lilly, Merck & Co., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, and more.

The bisphosphonate segment dominated the market share in 2024, while the hormone replacement therapy segment is expected to grow the fastest during the forecast period.

The hospital pharmacies segment held the largest market share in 2024, with online pharmacies expected to be the fastest-growing segment in the future.

North America dominated the market in 2024, while the Asia Pacific region is expected to experience the fastest growth due to increasing elderly populations and healthcare spending.

Recent developments include new data on fracture risk reduction with Prolia and FDA approval of a generic version of Forteo.

The report provides detailed segmentation analysis by drug class, route of administration, gender, and distribution channel.

For more information or to customize research on the Osteoporosis Treatment Market, visit the provided link.

Read more at GlobeNewswire: Osteoporosis Treatment Market Size to Reach $20.99 Billion